Hosted on MSN
INB-100 shows promise in AML patient remission rates
NEW YORK - IN8bio, Inc. (NASDAQ:INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies, reported positive clinical data from a Phase 1 trial of INB-100, an allogeneic ...
NEW YORK - IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies with a current market capitalization of $23.42 million, has announced encouraging Phase ...
IN8bio announces INB-619, a novel γδ T cell therapy platform targeting CD19, showing promise in B cell depletion with reduced side effects. IN8bio, Inc. has announced the launch of its innovative γδ T ...
INB-200 shows significantly improved progression-free survival in glioblastoma patients, with favorable safety profile and no serious toxicities reported. Repeated doses of INB-200 demonstrated an ...
Powerful B cell Targeting: INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, demonstrating potential as a treatment for autoimmune ...
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (INAB) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback